LONG READControl of empty, full and partially filled capsids BioPhorum establishing an industry position on this critical quality attributePosition A consensus of BioPhorum member companies reject a proposed blanket minimum specification for percentage empty AAV capsids. Presently, it is premature and impractical to set a minimal specification of <30% empty capsids to apply to all AAV-based gene therapies in development.BioPhorum calls upon...
Publication
Viewing related articles
Reflections on Covid-19 inbound supply chain issues
Nov 2021 | COVID 19, Long Read, Microbial Control, Publication
LONG READReflections on Covid-19 inbound supply chain issuesCovid-19 has had a significant impact throughout the biopharmaceutical industry, not least on the inbound supply chain, which has been hit by issues such as restricted supplies, the need for new sourcing strategies and how to design and build new facilities.To assess the issues, major supply partners (MSPs) were invited to submit questions to the biomanufacturing members of the Senior...
How industry is reacting to the Covid-19 pandemic
Jan 2021 | Cell & Gene Therapy, COVID 19, Covid-19, Deliverables Report, Development Group, Drug Substance, Fill Finish, Information Technology, Long Read, MediPhorum, Publication, Regulatory, Supply Partner, Technology Strategy
LONG READHow industry is reacting to the Covid-19 pandemicKeeping in touch with peers and colleagues has never been more important. Following the postponement of meetings such as the annual Executive BioPhorum meeting, coupled with the heightened need for communication between industry leaders, BioPhorum established the Senior BioPhorum Connect – a group for senior leaders to share ideas, discuss problems and find solutions to counter the...